Promising Results for New Scleroderma Drug from BLR Bio at Major Rheumatology Conference

Promising New Scleroderma Drug Data Revealed by BLR Bio

At the 2026 British Society of Rheumatology conference held in Glasgow, Scotland, BLR Bio, a company incubated at Rosalind Franklin University, unveiled significant findings regarding its investigational drug, BLR-200. The drug shows considerable promise in combatting systemic sclerosis, a rare and debilitating autoimmune disorder.

Dr. Bruce Riser, CEO of BLR Bio and adjunct professor at RFU’s Center for Cancer Cell Biology, Immunology, and Infection, expressed optimism about the potential impact of BLR-200. He stated, "Our goal is to provide relief and healing to patients suffering from this devastating disease. The ability of BLR-200 to disrupt crucial biological pathways involved in fibrosis is promising."

Systemic sclerosis is characterized by the hardening and scarring of connective tissues, impacting the skin, joints, and internal organs, particularly vital ones like the heart and lungs. With about 300,000 Americans diagnosed, predominantly women, the illness is associated with severe complications and diminished quality of life. Notably, more than 80% of patients are female, and there are currently no FDA-approved treatments specifically targeting the skin manifestations of this condition.

BLR Bio's recent presentation highlighted BLR-200's unique mechanism of action. Their research employed in vivo modeling using bleomycin to induce symptoms similar to those of systemic sclerosis. Advanced techniques such as single-cell RNA sequencing disclosed a specific population of skin fibroblasts, marked by profibrotic indicators like engrailed-1 and COL8A1. This particular cell subset is believed to drive the fibrosis associated with the disease. Remarkably, treatment with BLR-200 resulted in the elimination of these cells, thereby averting skin thickening and fibrosis in treated subjects.

Dr. Riser emphasized the importance of these findings, stating, "It is exciting to discover that BLR-200 effectively suppresses the activation of fibroblasts responsible for scar formation. Previous studies indicated that similar fibroblast populations exist in human scleroderma, leading to excessive collagen production, a hallmark of the disease. Our therapy stands apart from others by targeting this specific cell group. Furthermore, BLR-200's modulation of YAP nuclear translocation presents a promising direction in fibrotic disease therapy."

The research was conducted in collaboration with several prominent institutions, including the University of Saskatchewan in Canada and the University of Michigan. The findings align with previous studies that indicate an origin of skin fibrosis in scleroderma from myofibroblasts exhibiting these same markers, reinforcing the therapeutic potential for BLR-200.

Additionally, BLR Bio has been investigating CCN proteins, which play a significant role in cellular signaling and tissue repair, aiming to identify them as non-invasive biomarkers for systemic sclerosis. Their research identified distinct patterns of serum levels of CCN3 and CCN2, highlighting the potential for CCN3 to serve as a differentiating biomarker between scleroderma patients and healthy individuals.

As BLR Bio advances its innovative research on peptide-based therapies targeting fibrosis and cancer, its primary operations continue to be based at RFU's Helix 51 incubator, fostering collaborations with other esteemed institutions.

Dr. Janice Urban, Interim Executive Vice President for Research at RFU, noted, "Scleroderma represents a significant challenge in autoimmune diseases with limited treatment options. We remain hopeful that Dr. Riser's expertise, coupled with the innovative approach of BLR Bio, will culminate in breakthroughs that enhance both the quality and longevity of life for those affected."

With Rosalind Franklin University’s commitment to research excellence and the development of therapies for complex diseases, the presentation from BLR Bio is a hopeful sign for patients grappling with scleroderma.